Copyright © Inderes 2011 - present. All rights reserved.

Orion

59.70 EUR

-1.00 %

14,136 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

-1.00 %
-0.58 %
-10.90 %
-2.93 %
+39.55 %
+33.53 %
+15.43 %
+51.95 %
+431.61 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
8.43B EUR
Turnover
20.84M EUR
P/E (adj.) (25e)
16.63
EV/EBIT (adj.) (25e)
13.07
P/B (25e)
6.56
EV/S (25e)
4.37
Dividend yield-% (25e)
2.85 %
Coverage
Recommendation
Accumulate
Target price
66.00 EUR
Updated
28.10.2025
Antti Siltanen
Antti Siltanen

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.2
2026

Annual report '25

24.3
2026

General meeting '26

23.4
2026

Interim report Q1'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
€180M Nubeqa Milestone Payment and Outlook Update: New Outlook Estimate for 2025, issued 3 December 2025 Revenue is estimated to be €1,820–1,900 million. Operating profit is estimated to be €590–670 million. Previous Outlook Estimate for 2025, issued 28 October 2025 Revenue is estimated...
yesterday
by Ilkka
22
Hi, below is an excerpt from Bayer’s 2024 annual report, showing the expiration dates of Nubeqa’s molecule patent in key markets. Typically, efforts are made to build other types of patent protection for drugs as well (such as formulation patents or indication patents). However, ...
11/7/2025, 7:30 AM
by Tuukka Hirvonen
21
OP reported that Orion’s partner Bayer released its Q3 report and as part of it, Nubeqa’s product sales. Nubeqa’s Q3 sales were 622 million euros, while Bloomberg’s consensus estimate was 575 million euros. A significant beat of estimates creates upward pressure on Q4/25 and next...
11/12/2025, 9:50 AM
by veronmaksaja
20
Quite a roast of Orion, worth watching! A couple of scattered observations: -Speculations about selling or spinning off parts of Orion don’t seem to be the primary projects, even though the uniqueness of the veterinary side was highlighted. For example, Mandatum was like a lion caged...
11/10/2025, 3:14 PM
by PörssiPatruuna
15
Here you can find a list of Nubeqa patents and their expiration dates: https://www.drugs.com/availability/generic-nubeqa.html. The compound patents appear to last until 2030-33, and thereafter formulation patents until 2036-42, depending on the patent.
11/6/2025, 4:12 PM
by jerej
14
First of all, thanks to Verner for the excellent and well-executed Roast format. I have watched many Roasts even from companies that don’t interest me at all, as the format itself is so good. Excellent question suggestions from fellow investors. For me, a big question regarding Orion...
11/9/2025, 1:59 PM
7
Right. Strange stock behavior - though the decline seems to have stopped. Bayer, at least, is up about 2%. We await a possible positive profit warning from Orion and hopefully new indications and permission for additional sales next year. At least early-stage prostate cancer (to ...
11/12/2025, 10:56 AM
by Jummijammi2
6
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.